Grant of Interim Extension of the Term of U.S. Patent No. 4,591,585; atamestane, 34896-34897 [E6-9489]
Download as PDF
<![CDATA[
34896
Federal Register / Vol. 71, No. 116 / Friday, June 16, 2006 / Notices
Partial Rescission of Review
On June 1, 2006, CES timely
withdrew its request for an
administrative review of its sales during
the above–referenced period. Section
351.213(d)(1) of the Department’s
regulations requires that the Secretary
rescind an administrative review if a
party requesting a review withdraws the
request within 90 days of the date of
publication of the notice of initiation. In
this case, CES has withdrawn its request
for review within the 90-day period. We
have received no other submissions
regarding CES’s withdrawal of its
request for review. Therefore, we are
rescinding in part this review of the
antidumping duty order on stainless
steel bar from the United Kingdom with
respect to CES. This review will
continue with respect to Firth Rixson.
This notice is published in
accordance with section 751 of the
Tariff Act of 1930, as amended, and 19
CFR 351.213(d)(4).
Dated: June 12, 2006.
Stephen J. Claeys,
Deputy Assistant Secretary for Import
Administration.
[FR Doc. E6–9474 Filed 6–15–06; 8:45 am]
Kate
Swails or Shane Guan (301)713–2289.
FOR FURTHER INFORMATION CONTACT:
BILLING CODE 3510–DS–S
National Oceanic and Atmospheric
Administration
[I.D. 060706D]
Endangered Species; File No. 1578
National Marine Fisheries
Service (NMFS), National Oceanic and
Atmospheric Administration (NOAA),
Commerce.
ACTION: Notice; Receipt of application.
wwhite on PROD1PC61 with NOTICES
AGENCY:
SUMMARY: Notice is hereby given that
the Maine Department of Marine
Resources (MDMR) (Gail S.
Wippelhauser, Principal Investigator),
21 State House Station, Augusta, ME
04333 has applied in due form for a
permit to take shortnose sturgeon
(Acipenser brevirostrum) for purposes of
scientific research.
DATES: Written, telefaxed, or e-mail
comments must be received on or before
July 17, 2006.
ADDRESSES: The application and related
documents are available for review
upon written request or by appointment
in the following office(s):
Permits, Conservation and Education
Division, Office of Protected Resources,
NMFS, 1315 East-West Highway, Room
13705, Silver Spring, MD 20910; phone
(301)713–2289; fax (301)427–2521; and
18:25 Jun 15, 2006
The
subject permit is requested under the
authority of the Endangered Species Act
of 1973, as amended (ESA; 16 U.S.C.
1531 et seq.) and the regulations
governing the taking, importing, and
exporting of endangered and threatened
species (50 CFR 222–226).
The applicant proposes to determine
the location of spawning and feeding
habitat, and migratory pathways of
sturgeon in the Penobscot and Kennebec
Rivers in Maine. The study would also
determine the impact of river flows on
migration and habitat use. Researchers
would annually capture up to 250
sturgeon from the Penobscot River
during the study’s first three years. Up
to 500 sturgeon would be captured
annually from the Kennebec River
during the last two years of the study.
Sturgeon would be captured with
gillnets, measured, weighed, tissue
sampled, Passive Integrated
Transponder tagged, and released. A
sample of sturgeon would be acoustic
tagged. Researchers would also sample
for eggs and larvae. The permit would
be issued for five-years.
SUPPLEMENTARY INFORMATION:
DEPARTMENT OF COMMERCE
VerDate Aug<31>2005
Northeast Region, NMFS, One
Blackburn Drive, Gloucester, MA 019302298; phone (978)281–9328; fax
(978)281–9394.
Written comments or requests for a
public hearing on this application
should be mailed to the Chief, Permits,
Conservation and Education Division,
F/PR1, Office of Protected Resources,
NMFS, 1315 East-West Highway, Room
13705, Silver Spring, MD 20910. Those
individuals requesting a hearing should
set forth the specific reasons why a
hearing on this particular request would
be appropriate.
Comments may also be submitted by
facsimile at (301)427–2521, provided
the facsimile is confirmed by hard copy
submitted by mail and postmarked no
later than the closing date of the
comment period.
Comments may also be submitted by
email. The mailbox address for
providing email comments is
NMFS.Pr1Comments@noaa.gov. Include
in the subject line of the email comment
the following document identifier: File
No. 1578.
Jkt 208001
Dated: June 12, 2006.
P. Michael Payne,
Chief, Permits, Conservation and Education
Division, Office of Protected Resources,
National Marine Fisheries Service.
[FR Doc. E6–9501 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–22–S
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0032]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,591,585;
atamestane
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a third one-year interim extension of the
term of U.S. Patent No. 4,591,585.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 9, 2006, Intarcia
Therapeutics, Inc., exclusive licensee of
U.S. Patent No. 4,591,585, assigned to
Schering Aktiengesellschaft, timely filed
an application under 35 U.S.C. 156(d)(5)
for a third interim extension of the term
of U.S. Patent No. 4,591,585. The patent
claims the human drug product
atamestane. The application indicates
that a New Drug Application for the
human drug product atamestane has
been filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the
extended expiration date of the patent
(June 18, 2006), interim extension of the
SUPPLEMENTARY INFORMATION:
E:\FR\FM\16JNN1.SGM
16JNN1
Federal Register / Vol. 71, No. 116 / Friday, June 16, 2006 / Notices
patent term under 35 U.S.C. 156(d)(5) is
appropriate.
A third interim extension under 35
U.S.C. 156(d)(5) of the term of U.S.
Patent No. 4,591,585 is granted for a
period of one year from the expiration
date of the patent, i.e., until June 18,
2007.
Dated: June 12, 2006.
Jon W. Dudas
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9489 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0033]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,585,597;
´
ANTHELIOS SP (HELIOBLOCK SX
Cream) (Mexoryl SX (Ecamsule))
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a fourth one-year interim extension of
the term of U.S. Patent No. 4,585,597.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On May 16, 2006, patent owner, L
Oreal S.A., timely filed an application
under 35 U.S.C. 156(d)(5) for a fourth
subsequent interim extension of the
term of U.S. Patent No. 4,585,597. The
patent claims the active ingredient
Mexoryl SX (ecamsule), in the human
drug product ANTHELIOS SP
(HELIOBLOCK SX Cream), a method of
wwhite on PROD1PC61 with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Aug<31>2005
18:25 Jun 15, 2006
Jkt 208001
use of the active ingredient, and a
method of manufacturing the active
ingredient. The application indicates,
and the Food and Drug Administration
has confirmed, that a New Drug
Application for the human drug product
Mexoryl SX (ecamsule) has been filed
and is currently undergoing regulatory
review before the Food and Drug
Administration for permission to market
or use the product commercially.
Review of the application indicates
that, except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for an additional year as
required by 35 U.S.C. 156(d)(5)(B).
Because it is apparent that the
regulatory review period will continue
beyond the extended expiration date of
the patent (June 16, 2006), interim
extension of the patent term under 35
U.S.C. 156(d)(5) is appropriate. A fourth
interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,585,597 is granted for a period of one
year from the extended expiration date
of the patent, i.e., until June 16, 2007.
Dated: June 12, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9490 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO–P–2006–0019]
Grant of Interim Extension of the Term
of U.S. Patent No. 4,850,962; Esteem
(Totally Implantable Hearing System)
United States Patent and
Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term
Extension.
AGENCY:
SUMMARY: The United States Patent and
Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for
a one-year interim extension of the term
of U.S. Patent No. 4,850,962.
FOR FURTHER INFORMATION CONTACT:
Mary C. Till by telephone at (571) 272–
7755; by mail marked to her attention
and addressed to the Commissioner for
Patents, Mail Stop Patent Ext., P.O. Box
1450, Alexandria, VA 22313–1450; by
fax marked to her attention at (571) 273–
7755, or by e-mail to
Mary.Till@uspto.gov.
PO 00000
Frm 00028
Fmt 4703
Sfmt 4703
34897
Section
156 of Title 35, United States Code,
generally provides that the term of a
patent may be extended for a period of
up to five years if the patent claims a
product, or a method of making or using
a product, that has been subject to
certain defined regulatory review, and
that the patent may be extended for
interim periods of up to a year if the
regulatory review is anticipated to
extend beyond the expiration date of the
patent.
On March 31, 2006, patent owner,
Envoy Medical Corporation, timely filed
an application under 35 U.S.C. 156(d)(5)
for an interim extension of the term of
U.S. Patent No. 4,850,962. The patent
claims the medical device Esteem
(totally implantable hearing system).
The application indicates that an
Investigational Device Exemption for
the medical device Esteem has been
filed and is currently undergoing
regulatory review before the Food and
Drug Administration for permission to
market or use the product commercially.
Review of the application indicates
that except for permission to market or
use the product commercially, the
subject patent would be eligible for an
extension of the patent term under 35
U.S.C. 156, and that the patent should
be extended for one year as required by
35 U.S.C. 156(d)(5)(B). Because it is
apparent that the regulatory review
period will continue beyond the original
expiration date of the patent (July 25,
2006), interim extension of the patent
term under 35 U.S.C. 156(d)(5) is
appropriate.
An interim extension under 35 U.S.C.
156(d)(5) of the term of U.S. Patent No.
4,850,962 is granted for a period of one
year from the original expiration date of
the patent, i.e., until July 25, 2007.
SUPPLEMENTARY INFORMATION:
Dated: June 12, 2006.
Jon W. Dudas,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. E6–9494 Filed 6–15–06; 8:45 am]
BILLING CODE 3510–16–P
COMMODITY FUTURES TRADING
COMMISSION
Sunshine Act Meeting
TIME AND DATE:
11 a.m., Friday, July 7,
2006.
1155 21st St., NW., Washington,
DC, 9th Floor Commission Conference
Room.
STATUS: Closed.
MATTERS TO BE CONSIDERED: Surveillance
Matters.
PLACE:
E:\FR\FM\16JNN1.SGM
16JNN1
]]>Agencies
[Federal Register Volume 71, Number 116 (Friday, June 16, 2006)]
[Notices]
[Pages 34896-34897]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9489]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
[Docket No. PTO-P-2006-0032]
Grant of Interim Extension of the Term of U.S. Patent No.
4,591,585; atamestane
AGENCY: United States Patent and Trademark Office, Commerce.
ACTION: Notice of Interim Patent Term Extension.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office has issued a
certificate under 35 U.S.C. 156(d)(5) for a third one-year interim
extension of the term of U.S. Patent No. 4,591,585.
FOR FURTHER INFORMATION CONTACT: Mary C. Till by telephone at (571)
272-7755; by mail marked to her attention and addressed to the
Commissioner for Patents, Mail Stop Patent Ext., P.O. Box 1450,
Alexandria, VA 22313-1450; by fax marked to her attention at (571) 273-
7755, or by e-mail to Mary.Till@uspto.gov.
SUPPLEMENTARY INFORMATION: Section 156 of Title 35, United States Code,
generally provides that the term of a patent may be extended for a
period of up to five years if the patent claims a product, or a method
of making or using a product, that has been subject to certain defined
regulatory review, and that the patent may be extended for interim
periods of up to a year if the regulatory review is anticipated to
extend beyond the expiration date of the patent.
On May 9, 2006, Intarcia Therapeutics, Inc., exclusive licensee of
U.S. Patent No. 4,591,585, assigned to Schering Aktiengesellschaft,
timely filed an application under 35 U.S.C. 156(d)(5) for a third
interim extension of the term of U.S. Patent No. 4,591,585. The patent
claims the human drug product atamestane. The application indicates
that a New Drug Application for the human drug product atamestane has
been filed and is currently undergoing regulatory review before the
Food and Drug Administration for permission to market or use the
product commercially.
Review of the application indicates that except for permission to
market or use the product commercially, the subject patent would be
eligible for an extension of the patent term under 35 U.S.C. 156, and
that the patent should be extended for one year as required by 35
U.S.C. 156(d)(5)(B). Because it is apparent that the regulatory review
period will continue beyond the extended expiration date of the patent
(June 18, 2006), interim extension of the
[[Page 34897]]
patent term under 35 U.S.C. 156(d)(5) is appropriate.
A third interim extension under 35 U.S.C. 156(d)(5) of the term of
U.S. Patent No. 4,591,585 is granted for a period of one year from the
expiration date of the patent, i.e., until June 18, 2007.
Dated: June 12, 2006.
Jon W. Dudas
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. E6-9489 Filed 6-15-06; 8:45 am]
BILLING CODE 3510-16-P
